Molecular epidemiology of human papillomavirus genotype in women with high‐grade squamous intraepithelial lesion and cervical cancer: Will a quadrivalent vaccine be necessary in Thailand?

Sukasem, Chonlaphat; Pairoj, Wantanich; Saekang, Nipa; Pombubpha, Hiranyaratsami; Srichunrasami, Chutatip; Pongtippan, Atcharaporn; Junyangdikul, Pairoj; Chantratita, Wasun

doi:10.1002/jmv.21948

Cited by 11 publications

(14 citation statements)

References 31 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Forty percent HSIL cytology samples were positive for HPV16 in our population. This rate is in similar with those reported from Thailand and Greece but is lower than Switzerland, New Mexico, United States …”

Section: Discussionsupporting

confidence: 91%

“…In summary, our results showed that 8.7% HSIL PT cytology samples were negative for hrHPV detection by FDA approved platform Aptima ® . This rate is slightly higher than that reported in the literature, which showed around 3–5% hrHPV negative HSIL cytology . This could be due to variation of HPV prevalence geographically and also due to the high risk nature of our patient population .…”

Section: Discussioncontrasting

confidence: 69%

“…Type‐specific distribution of hrHPV has been well studied and shows geographical variation. HPV16 is so far been reported to be the most prevalent hrHPV type in HSIL cytology samples across different populations . Forty percent HSIL cytology samples were positive for HPV16 in our population.…”

Section: Discussionmentioning

confidence: 49%

See 2 more Smart Citations

High grade squamous intraepithelial lesion on high‐risk HPV negative patients: Why we still need the Pap test

Sun

Masand

Patel

et al. 2018

Diagnostic Cytopathology

View full text Add to dashboard Cite

Background Cervical cancer is caused by high‐risk human papillomavirus (hrHPV). Though screening Pap test (PT) has reduced cancer mortality by detecting precursor lesions, there is now a move toward replacing screening PT with hrHPV testing. The aims of this study were to determine hrHPV negative rate in high grade squamous intraepithelial lesion (HSIL) PT in high‐risk patients and correlate with histopathology; and to review the hrHPV negative HSIL PT. Method LIS was searched (January 2015–June 2016) for HSIL PT results. Patient chart was reviewed for age, hrHPV co‐testing result including genotyping (Aptima®), and histopathology follow‐up (f/u) which was compared between hrHPV‐positive and hrHPV‐negative groups. hrHPV‐negative HSIL PT slides were re‐evaluated for concordance with original interpretation. Student t test was used for data analysis. Results There were 230 patients with HSIL PT who had hrHPV co‐testing and 199/230 had histopathological f/u. Majority (210/230, 91.3%) were hrHPV positive, and 20 (8.7%) were hrHPV negative. HrHPV negative HSIL was significantly more common in older women (mean age 49.3 years) compared with hrHPV‐positive HSIL (mean age 40.7 years) (P = .0015). The most frequently detected genotype was HPV16 (40%). F/u was CIN2/3 in 145/181 (80%) hrHPV‐positive HSIL (includes nine squamous cell carcinoma) and 6/16 (37.5%) hrHPV‐negative HSIL. Conclusion Although the risk of CIN2/3 and carcinoma was higher in hrHPV‐positive patients, possibility of hrHPV‐negative dysplastic lesions should be considered in older women as 6 of 16 (37.5%) of these women had CIN2/3 and/or carcinoma which would have been missed without the PT.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussioncontrasting

confidence: 69%

See 1 more Smart Citation

High grade squamous intraepithelial lesion on high‐risk HPV negative patients: Why we still need the Pap test

Sun

Masand

Patel

et al. 2018

Diagnostic Cytopathology

View full text Add to dashboard Cite

show abstract

“…[920] Studies from Thailand found a high prevalence of HPV 58, 33, and 68 among women with cervical pre-invasive lesions. [3738] Similar findings were reported from Uganda. [39] In Zambia, HPV 52, 53, and 58 were more common overall than 16 and 18.…”

Section: Anti-hpv Vaccination Of Femalessupporting

confidence: 82%

Are the currently existing anti-human papillomavirus vaccines appropriate for the developing world?

2013

Ann Med Health Sci Res

View full text Add to dashboard Cite

Cervical cancer prevention is expected to be achieved by vaccination of girls 2-3 years before sexual debut, and cervical smear cytology follow-up. The existing human papillomavirus (HPV) vaccines target the low-risk 6 and 11, and the high-risk 16 and 18 subtypes, the most common agents of ano-genital pre-invasive and invasive lesions. We conducted the review by searching PubMed using the terms “HPV,” “HPV subtypes,” “developing world,” and “HPV-vaccine” to retrieve articles published between 2000 and 2011. We focused on studies that were relevant to the developing world. The proposed vaccination policy is currently unachievable in the developing world because of the cost of the vaccine, the lack of adequate cytology and follow-up infrastructures. Moreover, the subtypes of HPV involved in cervical pathology, their associations, and natural history (clearance and persistence rates) differ from the industrialized world. Therefore, the current bivalent and quadrivalent anti-HPV vaccines are unlikely to achieve their target in the developing world. It follows from published data that there is an obligation of the pharmaceutical industry and of the public-health policy makers not to embark on mass vaccination campaigns without thorough information and investigation of the local relevance.

show abstract

“…INNO-LiPA (LiPA HBV GT; Innogenetics N.V., Ghent, Belgium) is based on the co-amplification of the 65 bp region of the HPV L1 gene and the 270 bp of the human HLA-DP1 gene using SPF10 biotinylated primers, followed by genotyping [53,54]. Some carcinogenic genotypes such as HPV-35, -39, -52, -56 and -66 were not covered by this method, and it was found to be the least effective genotyping for HPV-42 and -59 [33].…”

Section: Introductionmentioning

confidence: 99%

A review of methods for detect human Papillomavirusinfection

Abreu

Souza

Gimenes

et al. 2012

Virol J

219

181

View full text Add to dashboard Cite

Human Papillomavirus (HPV) is the most common sexually transmitted virus. Worldwide, the most common high-risk (HR)-HPV are -16/18, and approximately 70% of cervical cancers (CC) are due to infection by these genotypes. Persistent infection by HR-HPV is a necessary but not sufficient cause of this cancer, which develops over a long period through precursor lesions, which can be detected by cytological screening. Although this screening has decreased the incidence of CC, HPV-related cervical disease, including premalignant and malignant lesions, continues to be a major burden on health-care systems. Although not completely elucidated, the HPV-driven molecular mechanisms underlying the development of cervical lesions have provided a number of potential biomarkers for both diagnostic and prognostic use in the clinical management of women with HPV-related cervical disease, and these biomarkers can also be used to increase the positive predictive value of current screening methods. In addition, they can provide insights into the biology of HPV-induced cancer and thus lead to the development of nonsurgical therapies. Considering the importance of detecting HPV and related biomarkers, a variety of methods are being developed for these purposes. This review summarizes current knowledge of detection methods for HPV, and related biomarkers that can be used to discriminate lesions with a high risk of progression to CC.

show abstract

Molecular epidemiology of human papillomavirus genotype in women with high‐grade squamous intraepithelial lesion and cervical cancer: Will a quadrivalent vaccine be necessary in Thailand?

Cited by 11 publications

References 31 publications

High grade squamous intraepithelial lesion on high‐risk HPV negative patients: Why we still need the Pap test

High grade squamous intraepithelial lesion on high‐risk HPV negative patients: Why we still need the Pap test

Are the currently existing anti-human papillomavirus vaccines appropriate for the developing world?

A review of methods for detect human Papillomavirusinfection

Contact Info

Product

Resources

About